{"id":"budesonide-glycopyrronium-formoterol-fumarate","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Oral candidiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide suppresses inflammatory responses in the airways by binding glucocorticoid receptors. Formoterol activates beta-2 adrenergic receptors to increase cAMP and cause bronchodilation. Glycopyrronium blocks muscarinic acetylcholine receptors to prevent bronchoconstriction. Together, these three agents provide anti-inflammatory and dual bronchodilatory effects for sustained airway opening and reduced exacerbations.","oneSentence":"This triple-combination inhaler delivers a corticosteroid (budesonide) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrronium) to further relax airway smooth muscle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:55.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment (in some markets)"}]},"trialDetails":[{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT06283966","phase":"PHASE3","title":"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-21","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":5000},{"nctId":"NCT07414134","phase":"","title":"Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-10-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3598},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease","enrollment":22},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT06368427","phase":"","title":"Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":10},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT06321731","phase":"","title":"Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":718},{"nctId":"NCT06422676","phase":"","title":"MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":4},{"nctId":"NCT05573464","phase":"PHASE3","title":"A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-27","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":559},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT07103642","phase":"","title":"EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3402},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT06742736","phase":"","title":"EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":13000},{"nctId":"NCT05213611","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":150},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT05311306","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD in Germany","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":475},{"nctId":"NCT06723756","phase":"PHASE1","title":"A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":105},{"nctId":"NCT04609878","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-15","conditions":"Asthma","enrollment":2274},{"nctId":"NCT04609904","phase":"PHASE3","title":"Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-01","conditions":"Asthma","enrollment":2187},{"nctId":"NCT05915182","phase":"","title":"Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-07-21","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":218},{"nctId":"NCT06844175","phase":"","title":"Early Screening of Young COPD and Pre-COPD","status":"NOT_YET_RECRUITING","sponsor":"yanmengkang","startDate":"2025-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT05219630","phase":"","title":"Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":106},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT04600505","phase":"PHASE1","title":"A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":47},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT02536508","phase":"PHASE3","title":"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":627},{"nctId":"NCT03906045","phase":"PHASE1","title":"A Scintigraphy Study of PT010 in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-04-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":18},{"nctId":"NCT03836677","phase":"PHASE3","title":"A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-02-26","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":23},{"nctId":"NCT02465567","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-06-30","conditions":"COPD","enrollment":8588},{"nctId":"NCT03075267","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-04-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":96},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT04675463","phase":"NA","title":"The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD","status":"UNKNOWN","sponsor":"ShiYue Li","startDate":"2020-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT03740373","phase":"PHASE1","title":"A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-09-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT03081247","phase":"PHASE3","title":"To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Pearl Therapeutics, Inc.","startDate":"2018-04-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT01980615","phase":"PHASE1","title":"Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Budesonide/Glycopyrronium/Formoterol Fumarate","genericName":"Budesonide/Glycopyrronium/Formoterol Fumarate","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination inhaler delivers a corticosteroid (budesonide) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrronium) to further relax airway smooth muscle. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in some markets).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}